Colonization and infection with multiple nosocomial pathogens among patients colonized with vancomycin-resistant Enterococcus

Infection Control and Hospital Epidemiology

Volumn 24, Issue 4, 2003, Pages 242-245

  Donskey, Curtis J ^a   Ray, Amy J ^a   Hoyen, Claudia K ^b   Fuldauer, Peter D ^c   Aron, David C ^a   Salvator, Ann ^b   Bonomo, Robert A ^a  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM ISOLATION; CANDIDA ALBICANS; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; ENTEROCOCCUS; FECES ANALYSIS; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NURSING HOME; PREVALENCE;

AGED; CROSS INFECTION; ENTEROCOCCUS; HOSPITALS, VETERANS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; NURSING HOMES; PREVALENCE; RECTUM; RISK FACTORS; VANCOMYCIN RESISTANCE;

EID: 0037510021     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502207     Document Type: Article

References (12)

1. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-113.
2. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis 1997;25(suppl 2):S206-S210.
3. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996;22(suppl 2):S89-S94.
4. Muder RR, Brennen C, Drenning SD, Stout JE, Wagener MM. Multiply antibiotic-resistant gram-negative bacilli in a long-term-care facility: a case-control study of patient risk factors and prior antibiotic use. Infect Control Hosp Epidemiol 1997;18:809-813.
5. Paterson DL, Yu VL. Editorial response. Extended-spectrum B-lactamases: a call for improved detection and control. Clin Infect Dis 1999;29:1419-1422.
6. Garner JS. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996;17:53-80.
7. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Wayne, PA: National Committee for Clinical Laboratory Standards; 1993. Approved standard M7-A3.
8. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949:191-205.
9. Ostrowsky B, Steinberg JT, Farr B, Sohn AH, Sinkowitz-Cochran RL, Jarvis WR. Reality check: should we try to detect and isolate vancomycin-resistant enterococci patients? Infect Control Hosp Epidemiol 2001;22:116-119.
10. Eickhoff TC. VRE contact precautions: is the juice worth the squeeze? Infectious Disease News 2000;13:5.
11. Boyce JM, Opal SM, Chow JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994;32:1148-1153.
12. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343:1925-1932.